PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9275473-4	1996	The inhibitors of u-PA and plasmin, tranexamic acid and 6-aminocaproic acid, obviously inhibited the u-PA activity and the invasive potential of QBC939 cells.	Tranexamic Acid	36-51	plasminogen activator, urokinase	Homo sapiens	101-105	
9117184-8	1997	This effect could be inhibited by anti-u-PA antibodies, as well as by tranexamic acid and by aprotinin, indicating that the degrading activity is u-PA mediated and plasmin dependent.	Tranexamic Acid	70-85	plasminogen activator, urokinase	Homo sapiens	146-150	
22918041-7	2012	Treating of blood with tranexamic acid (60 mmol/l) was followed by decreased fibrinolytic potential of both exogenous tPA and uPA, despite uPA by itself is known to be not sensitive to aminocaproic acids.	Tranexamic Acid	23-38	plasminogen activator, urokinase	Homo sapiens	126-129	
33443933-8	2021	t-PA and u-PA-induced clot lysis were both inhibited in plasma from TXA-treated patients.	Tranexamic Acid	68-71	plasminogen activator, urokinase	Homo sapiens	9-13	
30575685-11	2019	Paradoxically, when fibrinolysis was induced by uPA, TXA treatment led to further increases in C5a production beyond uPA alone (p < 0.0001).	Tranexamic Acid	53-56	plasminogen activator, urokinase	Homo sapiens	48-51	
30575685-11	2019	Paradoxically, when fibrinolysis was induced by uPA, TXA treatment led to further increases in C5a production beyond uPA alone (p < 0.0001).	Tranexamic Acid	53-56	plasminogen activator, urokinase	Homo sapiens	117-120	
30575685-15	2019	Tranexamic acid may cause significant inflammatory C5a elevations in injured tissues by augmenting uPA-mediated plasmin generation in a fibrin-independent manner.	Tranexamic Acid	0-15	plasminogen activator, urokinase	Homo sapiens	99-102	
30451372-6	2019	However, large clinical trials show TXA becomes ineffective or harmful if treatment is delayed beyond 3 h. The mechanism is unknown but urokinase plasminogen activator (uPA) has been implicated.	Tranexamic Acid	36-39	plasminogen activator, urokinase	Homo sapiens	136-167	
30451372-6	2019	However, large clinical trials show TXA becomes ineffective or harmful if treatment is delayed beyond 3 h. The mechanism is unknown but urokinase plasminogen activator (uPA) has been implicated.	Tranexamic Acid	36-39	plasminogen activator, urokinase	Homo sapiens	169-172	
30451372-16	2019	Conclusions Tranexamic acid protects fibrin but stimulates uPA activity and slows inhibition of plasmin by alpha2 -antiplasmin.	Tranexamic Acid	12-27	plasminogen activator, urokinase	Homo sapiens	59-62	
22918041-7	2012	Treating of blood with tranexamic acid (60 mmol/l) was followed by decreased fibrinolytic potential of both exogenous tPA and uPA, despite uPA by itself is known to be not sensitive to aminocaproic acids.	Tranexamic Acid	23-38	plasminogen activator, urokinase	Homo sapiens	139-142	
22974122-6	2012	Urokinase plasminogen activator (u-PA)-catalyzed fibrinolysis was also inhibited by TA, even though Pgn activation could be stimulated.	Tranexamic Acid	84-86	plasminogen activator, urokinase	Homo sapiens	0-31	
22974122-6	2012	Urokinase plasminogen activator (u-PA)-catalyzed fibrinolysis was also inhibited by TA, even though Pgn activation could be stimulated.	Tranexamic Acid	84-86	plasminogen activator, urokinase	Homo sapiens	33-37	
18460030-13	2008	The addition of aprotinin, a serine proteinase inhibitor, and tranexamic acid, a uPA-plasmin inhibitor, inhibited the plasmin-induced impairment of BM assembly and facilitated BM reorganization, thereby improving the epidermal structure.	Tranexamic Acid	62-77	plasminogen activator, urokinase	Homo sapiens	81-84